136 related articles for article (PubMed ID: 30246858)
21. HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey.
Smith SC; Palanisamy N; Zuhlke KA; Johnson AM; Siddiqui J; Chinnaiyan AM; Kunju LP; Cooney KA; Tomlins SA
Am J Surg Pathol; 2014 May; 38(5):615-26. PubMed ID: 24722062
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic significance of mutually exclusive expression of ERG and SPINK1 in endocrine-treated prostatic cancer].
Teng L; Gao W; Lu D; Xu J; Zhao L
Zhonghua Bing Li Xue Za Zhi; 2014 Mar; 43(3):149-53. PubMed ID: 24842011
[TBL] [Abstract][Full Text] [Related]
23. Adenocarcinomas of the prostatic duct in necropsy material.
Stamatiou K; Alevizos A; Mariolis A; Fanou D; Alevizou A; Michalodimitrakis E; Sofras F
Can J Urol; 2007 Apr; 14(2):3502-6. PubMed ID: 17466156
[TBL] [Abstract][Full Text] [Related]
24. ERG oncoprotein expression in prostatic acinar adenocarcinoma; clinicopathologic significance.
Hashmi AA; Khan EY; Irfan M; Ali R; Asif H; Naeem M; Nisar L; Faridi N; Khan A; Edhi MM
BMC Res Notes; 2019 Jan; 12(1):35. PubMed ID: 30658688
[TBL] [Abstract][Full Text] [Related]
25. ERG expression in intraductal carcinoma of the prostate: comparison with adjacent invasive prostatic adenocarcinoma.
Schneider TM; Osunkoya AO
Mod Pathol; 2014 Aug; 27(8):1174-8. PubMed ID: 24406865
[TBL] [Abstract][Full Text] [Related]
26. Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.
Fontugne J; Cai PY; Alnajar H; Bhinder B; Park K; Ye H; Beg S; Sailer V; Siddiqui J; Blattner-Johnson M; Croyle JA; Noorzad Z; Calagua C; MacDonald TY; Axcrona U; Bogaard M; Axcrona K; Scherr DS; Sanda MG; Johannessen B; Chinnaiyan AM; Elemento O; Skotheim RI; Rubin MA; Barbieri CE; Mosquera JM
JCI Insight; 2022 Feb; 7(4):. PubMed ID: 35050902
[TBL] [Abstract][Full Text] [Related]
27. Determination of ERG(+), EZH2, NKX3.1, and SPINK-1 subtypes to evaluate their association with clonal origin and disease progression in multifocal prostate cancer.
Segura-Moreno YY; Sanabria-Salas MC; Mesa-López De Mesa JA; Varela-Ramirez R; Acosta-Vega NL; Serrano ML
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1728. PubMed ID: 36199157
[TBL] [Abstract][Full Text] [Related]
28. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
Huang KC; Evans A; Donnelly B; Bismar TA
Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
[TBL] [Abstract][Full Text] [Related]
29. Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication.
Abdelsalam RA; Khalifeh I; Box A; Kalantarian M; Ghosh S; Abou-Ouf H; Lotfi T; Shahait M; Palanisamy N; Bismar TA
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1701-1709. PubMed ID: 32350606
[TBL] [Abstract][Full Text] [Related]
30. Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension.
Samaratunga H; Duffy D; Yaxley J; Delahunt B
Hum Pathol; 2010 Feb; 41(2):281-5. PubMed ID: 20004936
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
[TBL] [Abstract][Full Text] [Related]
32. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
[TBL] [Abstract][Full Text] [Related]
33. Prostate cancer SubtyPINg biomarKers and outcome: is clarity emERGing?
Smith SC; Tomlins SA
Clin Cancer Res; 2014 Sep; 20(18):4733-6. PubMed ID: 24944315
[TBL] [Abstract][Full Text] [Related]
34. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
Sabaliauskaite R; Jarmalaite S; Petroska D; Dasevicius D; Laurinavicius A; Jankevicius F; Lazutka JR
Genes Chromosomes Cancer; 2012 Aug; 51(8):781-91. PubMed ID: 22505341
[TBL] [Abstract][Full Text] [Related]
35. Foamy gland carcinoma of the prostate in needle biopsy: incidence, Gleason grade, and comparative α-methylacyl-CoA racemase vs. ERG expression.
Warrick JI; Humphrey PA
Am J Surg Pathol; 2013 Nov; 37(11):1709-14. PubMed ID: 23797726
[TBL] [Abstract][Full Text] [Related]
36. Heterogenous expression of ERG oncoprotein in Malaysian men with adenocarcinoma of the prostate.
Tan JSJ; Ong KC; Ong DBL; Razack A; Lim J; Yunus R; Sundram M; Rhodes A
Malays J Pathol; 2018 Aug; 40(2):103-110. PubMed ID: 30173226
[TBL] [Abstract][Full Text] [Related]
37. The role of SPINK1 in ETS rearrangement-negative prostate cancers.
Tomlins SA; Rhodes DR; Yu J; Varambally S; Mehra R; Perner S; Demichelis F; Helgeson BE; Laxman B; Morris DS; Cao Q; Cao X; Andrén O; Fall K; Johnson L; Wei JT; Shah RB; Al-Ahmadie H; Eastham JA; Eggener SE; Fine SW; Hotakainen K; Stenman UH; Tsodikov A; Gerald WL; Lilja H; Reuter VE; Kantoff PW; Scardino PT; Rubin MA; Bjartell AS; Chinnaiyan AM
Cancer Cell; 2008 Jun; 13(6):519-28. PubMed ID: 18538735
[TBL] [Abstract][Full Text] [Related]
38. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
Tavora F; Epstein JI
Am J Surg Pathol; 2008 Jul; 32(7):1060-7. PubMed ID: 18496142
[TBL] [Abstract][Full Text] [Related]
39. Improved differentiation between ductal and acinar prostate cancer using three-dimensional histology and biomarkers.
Tarján M; Chen HH; Tot T; Wu W; Lenngren A; Dean PB; Tabár L
Scand J Urol Nephrol; 2012 Aug; 46(4):258-66. PubMed ID: 22519924
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
Dhani NC; Emmenegger U; Adams L; Jongstra J; Tannock IF; Sridhar SS; Knox JJ; Day JR; Groskopf J; Joshua AM
BJU Int; 2012 Sep; 110(6):840-5. PubMed ID: 22313860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
